SCHEMBL2657232

SCHEMBL2657232

CC1(C)OC(=O)[C@@H](CNC(=O)O)O1

nearest known ligand 0.41

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
GLS O94925 1/20 0.41
BACE1 P56817 1/20 0.35
TSHR P16473 1/20 0.32
GLA P06280 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL200462 0.77 GLS (0.47) GLSBACE1TSHR
SCHEMBL473047 0.77 GLS (0.47) GLSBACE1TSHR
SCHEMBL1005092 0.77 GLS (0.47) GLSBACE1TSHR
SCHEMBL2647395 0.76 LMNA (0.47)
SCHEMBL9460988 0.75 GLS (0.46) GLS
SCHEMBL21726165 0.74 GLS (0.40) GLSBACE1GLANPSR1
SCHEMBL21726166 0.74 GLS (0.40) GLSBACE1GLANPSR1
SCHEMBL9196022 0.74 GLS (0.40) GLSBACE1GLANPSR1
SCHEMBL18914987 0.73 GLS (0.47) GLSBACE1
SCHEMBL18219056 0.73 GLS (0.47) GLSBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590336-B1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME (US) 2010-12-01 EP disclosed
US-20090286875-A1 ISOCYSTENE DERIVATIVES FOR THE TREATMENT OF PAIN PFIZER, INC. (US) 2009-11-19 US disclosed
US-20090215825-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME LLC 2009-08-27 US disclosed
US-7572922-B2 Substituted pyrazoles, compositions containing such compounds and methods of use MERCK & CO., INC. (US) 2009-08-11 US disclosed
EP-1569915-A4 SPIROCYCLIC UREAS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO INC (US) 2007-07-11 EP disclosed
US-20060116366-A1 Spirocyclic ureas, compositions containing such compounds and methods of use MERCK & CO., INC. 2006-06-01 US disclosed
US-20060084681-A1 Substituted pyrazoles, compositions containing such compounds and methods of use MERCK SHARP & DOHME LLC 2006-04-20 US disclosed
EP-1590336-A2 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE Merck & Co., Inc. (US) 2005-11-02 EP disclosed
EP-1569915-A2 SPIROCYCLIC UREAS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE Merck & Co., Inc. (US) 2005-09-07 EP disclosed
WO-2004069158-A2 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 2004-08-19 WO disclosed
WO-2004050039-A2 SPIROCYCLIC UREAS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215825-A1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE GLP1R, GCGR, GPR119 GLS 47/4885BACE1 1909/4885TSHR 254/4885
US-20060084681-A1 Substituted pyrazoles, compositions containing such compounds and methods of use GLP1R, GCGR, GPR119 GLS 47/4885BACE1 1909/4885TSHR 254/4885
US-20060116366-A1 Spirocyclic ureas, compositions containing such compounds and methods of use UTS2R, GLP1R, GCGR GLS 141/4885BACE1 4655/4885TSHR 214/4885
US-20090286875-A1 ISOCYSTENE DERIVATIVES FOR THE TREATMENT OF PAIN IDH3A, ACHE, SDHA GLS 3046/4885BACE1 2978/4885TSHR 2185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.